What is Biofil Chemicals & Pharmaceuticals Ltd's market cap?

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) has a market capitalization of ₹59 Cr.

What sector is BIOFILCHEM in?

Biofil Chemicals & Pharmaceuticals Ltd operates in the Pharmaceuticals — Formulations & API sector.

What is BIOFILCHEM's return on equity?

Biofil Chemicals & Pharmaceuticals Ltd has a return on equity (ROE) of 55.1%.

Loading company...

Analyzing...

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) — Analysis, Financials, Intelligence | The Stock Filter

The Organism · Company Intelligence

Biofil Chemicals & Pharmaceuticals Ltd

BIOFILCHEM|BSE: 524396

Pharmaceuticals — Formulations & APIHealthcare & Life Scienceswww.biofilgroup.net

₹35.11

₹0.79 (-2.20%)|MCap ₹59 Cr

As of 16 Jun 2026 (End of Day)

52W Low ₹25.6052W High ₹55.19

Biofil Chemicals & Pharmaceuticals Ltd. engages in the manufacturing of pharmaceutical products. The company is headquartered in Indore, Madhya Pradesh. The firm operates through two segments: Pharma

Secular Currents

Theme Connections

Pharma CDMO Specialty Chemicals Healthcare Access

Intelligence Profile

TSF Score

50/100

The Vitals · Company Health

Health Indicators

Shenanigan Score

5Clean

Trust Score

X-Ray

Concerns

No significant concerns identified

Watch

Nothing flagged for monitoring

Strengths

🟢Strong return on equity (55.1%)Business
🟢Efficient capital deployment (ROCE: 15.0%)Business
🟢Low leverage (D/E: —)Business

The Numbers · Key Metrics

ROE

55.1%

₹59 Cr

The Narrator · StoryTel Intelligence

FY2025Pharmaceuticals — Formulations & APIProduct Sales ModelModel:Revenue = Volume of Drugs Sold × Average Selling Price (Domestic + Export)

Key Insight

“Operates in Pharmaceuticals — Formulations & API.”

The Revenue Story

₹33 Cr revenue.

Total Income₹34 Cr

Revenue₹33 Cr(99.1% of Total Income)

Other Income₹0.31 Cr(0.9% of Total Income)

The Cost Story

COGS 92.3%, employees 2.4%.

Cogs₹31 Cr(90.4%)

EBITDA₹1 Cr(3.4%)

Other Expenses₹0.92 Cr(2.7%)

Employee₹0.79 Cr(2.3%)

Depreciation₹0.38 Cr(1.1%)

Finance Costs₹0.04 Cr(0.1%)

0.1%EBITDA Margin

Cogs

90.4%

EBITDA

3.4%

Other Expenses

2.7%

Employee

2.3%

Depreciation

1.1%

Finance Costs

0.1%

Key Metrics

ROE

55.1%

vs median 10.5%

ROCE

15.0%

vs median 13.8%

Net Margin

8.6%

vs median 8.7%

EBITDA Margin

10.9%

vs median 16.0%

The Context · Where does it sit?

Sector Context

The Canopy · Sector KPIs

Sector KPIs

Pharmaceuticals — Formulations & API

KPI	Company	Sector Median
ROE	55.1%▲	10.5%
ROCE	15.0%▲	13.8%
Net Margin	8.6%▼	8.7%
EBITDA Margin	10.9%▼	16.0%

The Market · What is the market saying?

Market Signals

The Antenna · Media Intelligence

Media Signal

Low Impact

The Numbers · Show me the data

Financials

No valuation data

Historical valuation data not available.

Financials

Revenue₹33 Cr

PBT₹0.74 Cr

EPS₹0.34

(₹ Cr)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	₹33 Cr -16.6%	₹40 Cr +33.3%	₹30 Cr +34.2%	₹22 Cr -37.4%	₹36 Cr +20.4%	₹30 Cr +28.4%	₹23 Cr
Other Income	₹0.31 Cr -37.7%	₹0.49 Cr +404.8%	₹0.10 Cr -35.5%	₹0.15 Cr -81.3%	₹0.80 Cr +369.1%	₹0.17 Cr +69.5%	₹0.10 Cr
Total Income	₹34 Cr -16.8%	₹41 Cr +34.5%	₹30 Cr +33.7%	₹23 Cr -38.4%	₹37 Cr +22.4%	₹30 Cr +28.5%	₹23 Cr
COGS	₹31 Cr -17.8%	₹38 Cr +36.8%	₹27 Cr +40.9%	₹19 Cr -40.0%	₹32 Cr +28.1%	₹25 Cr +26.6%	₹20 Cr
	₹33 Cr -16.9%	₹40 Cr +35.2%	₹29 Cr +36.3%	₹22 Cr -37.9%	₹35 Cr +22.0%	₹28 Cr +25.5%	₹23 Cr
Profit Before Tax	₹0.74 Cr -14.9%	₹0.87 Cr +9.1%	₹0.79 Cr -21.9%	₹1 Cr -47.2%	₹2 Cr +31.4%	₹1 Cr +144.7%	₹0.60 Cr
	₹0.18 Cr +14.2%	₹0.16 Cr -32.9%	₹0.23 Cr -26.5%	₹0.32 Cr -53.3%	₹0.68 Cr +163.8%	₹0.26 Cr +121.5%	₹0.12 Cr
Net Profit	₹0.56 Cr -21.4%	₹0.71 Cr +26.6%	₹0.56 Cr -19.8%	₹0.70 Cr -43.9%	₹1 Cr +3.2%	₹1 Cr +150.3%	₹0.48 Cr
Other Comprehensive Income	₹0.02 Cr -89.1%	₹0.19 Cr ↑ Recovery	(₹0.10 Cr) ↓ Decline	₹0.01 Cr +124.4%	₹0.00 Cr -82.8%	₹0.03 Cr	₹0.00 Cr
EPS	₹0.34	₹0.44	₹0.34	₹0.43	₹0.77	₹0.74	₹0.30
Diluted Shares	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr

The Stakeholders · Ownership Pattern

Ownership

The Board · Corporate Governance

Governance

Trust55

No related party data available for this company.

This section will be populated when data becomes available.

The Evidence · Sources & Filings

Evidence

No concall transcripts available

No transcripts

No earnings call transcripts available.

Announcements

48 filings

Copy of Newspaper Publication1 Jun 2026

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2...

PDF

Disclosure under SEBI Takeover Regulations7 May 2026

KETAN SHAH has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

PDF

Updates5 May 2026

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Intimation...

PDF

Trading Window24 Mar 2026

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

PDF

Copy of Newspaper Publication14 Feb 2026

PDF

Outcome of Board Meeting13 Feb 2026

Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

PDF

Price movement3 Feb 2026

Significant movement in price has been observed in Biofil Chemicals & Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to...

PDF

Price movement3 Feb 2026

PDF

Certificate under SEBI (Depositories and Participants) Regulations, 20182 Jan 2026

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

PDF

Trading Window23 Dec 2025

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

PDF

Action(s) taken or orders passed3 Dec 2025

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

PDF

Action(s) taken or orders passed26 Nov 2025

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

PDF

Copy of Newspaper Publication15 Nov 2025

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

PDF

Outcome of Board Meeting13 Nov 2025

Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

PDF

Certificate under SEBI (Depositories and Participants) Regulations, 20184 Oct 2025

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

PDF

Peer Comparison

Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.

Last synced: 29 Mar 2026

Data source: Public filings via TSF Bedrock

Biofil Chemicals & Pharmaceuticals Ltd

Theme Connections

Intelligence Profile

Health Indicators

X-Ray

Concerns

Watch

Strengths

Sector Context

Sector KPIs

Market Signals

Media Signal

Financials

No valuation data

Financials

Ownership

Governance

Evidence

No transcripts

Announcements

Peer Comparison

Growth (CAGR)

Key Ratios

Profitability

Leverage

Growth

No dividend data